Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Debashish, Misra"'
Publikováno v:
Clinical Case Reports, Vol 7, Iss 11, Pp 2068-2073 (2019)
Abstract Current safety data affirms enzalutamide does not cause clinically significant liver dysfunction that warrant therapy cessation. Therefore, clinicians should not withhold potentially successful therapy merely for suspected hepatotoxicity or
Externí odkaz:
https://doaj.org/article/6285a86d2e1644e8a20c7cea566387ec
Publikováno v:
Clinical Case Reports
Clinical Case Reports, Vol 7, Iss 11, Pp 2068-2073 (2019)
Clinical Case Reports, Vol 7, Iss 11, Pp 2068-2073 (2019)
Current safety data affirms enzalutamide does not cause clinically significant liver dysfunction that warrant therapy cessation. Therefore, clinicians should not withhold potentially successful therapy merely for suspected hepatotoxicity or PnC.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::327bd6c1e674f5711a3bf864cd916610
https://doi.org/10.1002/ccr3.2427
https://doi.org/10.1002/ccr3.2427
Autor:
Vic Hasselblad, Dong-Feng Chen, John P. Chute, Gwynn D. Long, Patrick G. Green, Yiping Yang, Nelson J. Chao, Megan Baker, Keith M. Sullivan, Ashley Morris, Debashish Misra, Daniel A. Nikcevich, Mitchell E. Horwitz, Therese Hennig, Christine Apple, Cristina Gasparetto, Robert W. Storms, David A. Rizzieri
Infusing natural killer (NK) cells following transplantation may allow less infections and relapse with little risk of acute graft-versus-host disease (aGVHD). We delivered 51 total NK cell-enriched donor lymphocyte infusions (DLIs) to 30 patients fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8aed7a11513a1761a659f7b53f5d21d
https://europepmc.org/articles/PMC3625653/
https://europepmc.org/articles/PMC3625653/
Publikováno v:
Clinical advances in hematologyoncology : HO. 2(7)
A substantial increase in the number of elderly people in the populations of developed nations in the coming years has been projected. Persons 65 years and older are at significantly higher risk of developing cancer when compared to younger individua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ae69925b431c100fdd77a40b3e961d5b
https://pubmed.ncbi.nlm.nih.gov/16163222
https://pubmed.ncbi.nlm.nih.gov/16163222
Autor:
Ashley Morris, Mitchell E. Horwitz, Nelson J. Chao, Bercedis Peterson, Robert W. Storms, John P. Chute, Cristina Gasparetto, Debashish Misra, Megan Baker, Christine Apple, Daniel A. Nikcevich, David A. Rizzieri
Publikováno v:
Blood. 112:342-342
Introduction: Early response rates to non-myeloablative therapy are encouraging, however long term remissions remain elusive. Manipulating donor lymphocyte infusions (DLI) to preferentially infuse Natural Killer (NK) cells, typically comprising 3–5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8ba71fc938320f2509378b9146924aae
https://doi.org/10.1182/blood.v112.11.342.342
https://doi.org/10.1182/blood.v112.11.342.342
Autor:
Carlos M. de Castro, Nelson J. Chao, Jon P. Gockerman, Yiping Yang, Debashish Misra, Joseph O. Moore, Cristina Gasparetto, Bercedis Peterson, Louis F. Diehl, John P. Chute, Mitchell E. Horwitz, David A. Rizzieri, Amy Abernathy, Gwynn D. Long
Publikováno v:
Blood. 106:4623-4623
Purpose: To estimate the maximum tolerated duration (MTD) of gemcitabine given as a continuous infusion in combination with fludarabine and mitoxantrone for patients with relapsed or refractory leukemia. Patients and Methods: Patients received gemcit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6aca97c2e20923dcc828b39697243cd
https://doi.org/10.1182/blood.v106.11.4623.4623
https://doi.org/10.1182/blood.v106.11.4623.4623
Autor:
Patricia H. Davis, Carlos M. de Castro, Philip D. Hall, Cristina Gasparetto, Jennifer H Black, Nelson J. Chao, Jon P. Gockerman, Tie Fu Liu, Joseph O. Moore, David A. Rizzieri, Mitchell E. Horwitz, Debashish Misra, Arthur E. Frankel
Publikováno v:
Blood. 104:4513-4513
Background: Although complete remission rates for AML are near 70% with combination induction and consolidation chemotherapy, most patients will relapse and die from the disease or treatment complications. New agents with unique mechanisms are needed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf7c204c2260b5e6ad518e00ae6cf355
https://doi.org/10.1182/blood.v104.11.4513.4513
https://doi.org/10.1182/blood.v104.11.4513.4513